139 related articles for article (PubMed ID: 37852849)
1. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
Lu K; Woodward BD; Boys J; Onaitis M; Husain H
Clin Lung Cancer; 2024 Jan; 25(1):e58-e61. PubMed ID: 37852849
[No Abstract] [Full Text] [Related]
2. Patients with uncommon EGFR mutations also benefit from first-line osimertinib.
Romero D
Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38057403
[No Abstract] [Full Text] [Related]
3. Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
Wang VE; Gainor JF
JAMA Oncol; 2024 Jan; 10(1):52-53. PubMed ID: 37991771
[No Abstract] [Full Text] [Related]
4. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Bonanno L; Dómine M; Poole L; Bolanos A; Rukazenkov Y; Wu YL
Target Oncol; 2024 Mar; 19(2):131-134. PubMed ID: 38466534
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
6. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Moik F; Riedl JM; Ay C
Ann Oncol; 2024 Mar; 35(3):327. PubMed ID: 38092622
[No Abstract] [Full Text] [Related]
7. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
Remon J; Saw SPL; Cortiula F; Singh PK; Menis J; Mountzios G; Hendriks LEL
J Thorac Oncol; 2024 Feb; 19(2):199-215. PubMed ID: 37783386
[TBL] [Abstract][Full Text] [Related]
8. Lazarus effect in a patient initially empirically treated with osimertinib for
Bhatia S; Cortez MG; Lessans S; Iams WT
Oncotarget; 2024 Jan; 15():27-30. PubMed ID: 38227738
[TBL] [Abstract][Full Text] [Related]
9. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Lim SM; Lee JB; Cho BC
J Thorac Oncol; 2024 Mar; 19(3):376-379. PubMed ID: 38453325
[No Abstract] [Full Text] [Related]
11. Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
Passaro A; Wang J; Shah S; Bauml JM; Campelo RG; Cho BC
Ann Oncol; 2024 Mar; 35(3):328-329. PubMed ID: 38029840
[No Abstract] [Full Text] [Related]
12. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Chen LN; Lee ATM; Nagasaka M; Ou SI
J Thorac Oncol; 2024 Mar; 19(3):380-384. PubMed ID: 38453326
[No Abstract] [Full Text] [Related]
13. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
Yu Z; Xu F; Zou J
Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
[TBL] [Abstract][Full Text] [Related]
14. CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.
Al-Obeidi E; Kelly K; Gandara DR; Riess JW
JCO Precis Oncol; 2024 Apr; 8():e2300677. PubMed ID: 38603654
[TBL] [Abstract][Full Text] [Related]
15. Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib.
Bennett P; Finall A; Medeiros F; Gerrard G; Taniere P
Eur J Cancer; 2022 Oct; 174():315-317. PubMed ID: 35934607
[No Abstract] [Full Text] [Related]
16. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
van Waalwijk van Doorn-Khosrovani SB; Badrising SK; Burgers S
N Engl J Med; 2024 Feb; 390(5):478. PubMed ID: 38294983
[No Abstract] [Full Text] [Related]
18. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
[TBL] [Abstract][Full Text] [Related]
19. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
Rotow JK; Lee JK; Madison RW; Oxnard GR; Jänne PA; Schrock AB
J Thorac Oncol; 2024 Feb; 19(2):227-239. PubMed ID: 37806383
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
Planchard D; Jänne PA; Kobayashi K
N Engl J Med; 2024 Feb; 390(5):478-479. PubMed ID: 38294984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
